Shanghai Jiaotong University publishes a long review of Nature:

[1] Wang C, et al.

[2] Bray F, et al.

[3] Allemani C, et al.

[4] Villanueva A.

[5] Zucman-Rossi J, et al.

[6] Kudo M, et al.

[7] Finn RS, et al.

[8] Finn RS, et al.

[9] Ren Z, et al.

[10] Llovet JM, et al.

[11] Shalem O, et al.
High-throughput functional genomics using CRISPR-Cas9.
Nat Rev Genet.
2015, 16:299-311.

[12] Wang C, et al.
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Nature.
2019, 574(7777):268-272.

[13] Wang C, et al.
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Gut.
2020, 69(4):727-736.

[14] Wang C, et al.
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.
Cell Res.
2018, 28(6):690-692.

[15] Wang C, et al.
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.
J Hepatol.
2018, 69(5):1057-1065.

Link to this article: https://